Navigation Links
Appointment of Mr. Kevin Buchi to Benitec Board

SYDNEY, April 10, 2013 /PRNewswire/ -- Benitec Biopharma Ltd (ASX: BLT), a biopharmaceutical company developing innovative therapeutics based on its gene silencing technology, DNA-directed RNA interference (ddRNAi), is very pleased to report that Mr. Kevin Buchi , CPA, has accepted an invitation to join the Company's Board of Directors. 

Mr. Buchi served as Chief Executive Officer of Cephalon, Inc. through its $6.8 billion acquisition by Teva Pharmaceutical Industries in October 2011. After the acquisition Mr. Buchi served as Corporate Vice President, Global Branded Products of Teva Pharmaceuticals. Mr. Buchi joined Cephalon in 1991 and held various positions, including Chief Operating Officer, Chief Financial Officer and Head of Business Development prior to being appointed CEO.

Mr. Buchi currently serves on the Board of Directors of Stemline Therapeutics, Inc., Forward Pharma A/S and Alexza Pharmaceuticals, Inc. Mr. Buchi has served on the Board of Directors of Lorus Therapeutics (Canada), Encysive Pharmaceuticals, Inc., Celator Pharmaceuticals, Inc. and Mesoblast Limited (Australia). Mr. Buchi has served as a Member of the Life Sciences Advisory Board at Safeguard Scientifics, Inc.

Mr. Buchi originally trained as a synthetic organic chemist for the Eastman Kodak Company graduating from Cornell University with a Bachelor of Arts degree in chemistry. He holds a Master's degree in management from the Kellogg Graduate School of Management at Northwestern University and is a Certified Public Accountant. He resides in Pennsylvania in the United States.

Benitec Biopharma's Chairman, Mr. Peter Francis , welcomed Mr Buchi's appointment. "Kevin's impressive track record in the international biotechnology and pharmaceutical industry over 30 years provides Benitec with significant additional business development strength, and importantly, networking capacity in the United States and Europe. The Directors and Management look forward to working closely with Kevin to achieve the Company's aims through industry partnerships. We see this as a validation of Benitec's corporate strategy over the past few years."

Mr. Buchi commented, "I continue to be impressed with Benitec's programs and progress. The expected entry of the Company's Hepatitis C therapy into the clinic later this year is validation of that progress.  I believe that Benitec Biopharma's technology and programs have the potential to bring about a revolution in treatment of many diseases and conditions through the power of DNA-directed RNA interference. I look forward to working with the Company to help advance its exciting programs and vision."

For more information please contact:
Dr. Peter French | Chief Executive Officer
Phone: +61 (02) 9555 6986 | |

About Benitec Biopharma Limited:
Benitec Biopharma Limited is an ASX-listed biotechnology company (ASX Code: BLT) based in Sydney, Australia. The company has a pipeline of in-house and partnered therapeutic programs based on its patented gene-silencing technology, ddRNAi. Benitec is developing treatments for chronic and life-threatening human conditions such as Hepatitis C, Hepatitis B, wet age-related macular degeneration, cancer-associated pain, drug resistant lung cancer and oculopharyngeal muscular dystrophy based on this technology. In addition, Benitec has licensed ddRNAi technology to other biopharmaceutical companies who are progressing their programs towards the clinic for applications including HIV/AIDS, retinitis pigmentosa and Huntington's disease. For more information on Benitec refer to the Company's website at

SOURCE Benitec Biopharma Limited
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. National Honey Board Seeks Board Member Nominees: Appointments to be Made by United States Secretary of Agriculture
2. TaxOps Announces Partner Appointment to Prominent International Position with Fortune 100 Company
3. Store-A-Toothâ„¢ Stem Cell Banking Announces Appointment of Dedicated Sales Representative in New England
4. Aratana Therapeutics Adds Product Manufacturing Expertise with the Appointment of Two Senior Executives
5. PharmaDirections Announces Appointment of Dr. Bruce Rehlaender as Principal, Formulation Development
6. Mobility and Big Data Analytics Provider NuWare Announces the Appointment of Rohit Shyam as Chief Strategy & Marketing Officer
7. Store-A-Toothâ„¢ Dental Stem Cell Banking Announces Appointment of Dedicated Representative in South Florida
8. Sequenom Announces Leadership Appointments
9. T1D Exchange Announces Appointment of Dana Ball as Chief Executive Officer
10. Gallus BioPharmaceuticals Announces Appointment of Senior Baxter Executive as Chief Commercial Officer
11. Ampio Pharmaceuticals, Inc. (AMPE) announces appointment of Josh Disbrow as Chief Operating Officer effective December 15, 2012
Post Your Comments:
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... ... Program that includes over 2,000 technical presentations offered in symposia, oral sessions, ... and applied spectroscopy, covers a wide range of applications such as, but not ...
(Date:11/25/2015)... ANNAPOLIS, Md. , Nov. 25, 2015  PharmAthene, ... of Directors has adopted a stockholder rights plan (Rights ... its net operating loss carryforwards (NOLs) under Section 382 ... --> --> PharmAthene,s use of its ... an "ownership change" as defined in Section 382 of ...
(Date:11/25/2015)... QUEBEC CITY , Nov. 25, 2015 /PRNewswire/ ... "Company"), affirms that its business and prospects remain ... , Zoptrex™ (zoptarelin doxorubicin) recently received DSMB ... program to completion following review of the final ... met Phase 2 Primary Endpoint in men with ...
(Date:11/24/2015)... 24, 2015  Asia-Pacific (APAC) holds the third-largest ... market. The trend of outsourcing to low-cost locations ... higher volume share for the region in the ... margins in the CRO industry will improve. ... ( ), finds that the market earned ...
Breaking Biology Technology:
(Date:11/19/2015)... YORK , Nov. 19, 2015  Although some ... market is dominated by a few companies, according to ... companies own 51% of the market share of the ... The World Market for Molecular Diagnostic s ... "The market is still controlled by one company ...
(Date:11/17/2015)... LIVERMORE, Calif. , Nov. 17, 2015  Vigilant ... has joined its Board of Directors. ... Vigilant,s Board after recently retiring from the partnership at ... owning 107 companies with over $140 Billion in revenue.  ... performance improvement across all the TPG companies, from 1997 ...
(Date:11/12/2015)... , Nov. 11, 2015   Growing need ... analytical tools has been paving the way for ... determination of discrete analytes in clinical, agricultural, environmental, ... being predominantly used in medical applications, however, their ... sectors due to continuous emphasis on improving product ...
Breaking Biology News(10 mins):